ES2182996T3 - Composiciones farmaceuticas que comprenden un inhibidor de proteinasa y un monglicerido. - Google Patents

Composiciones farmaceuticas que comprenden un inhibidor de proteinasa y un monglicerido.

Info

Publication number
ES2182996T3
ES2182996T3 ES96921929T ES96921929T ES2182996T3 ES 2182996 T3 ES2182996 T3 ES 2182996T3 ES 96921929 T ES96921929 T ES 96921929T ES 96921929 T ES96921929 T ES 96921929T ES 2182996 T3 ES2182996 T3 ES 2182996T3
Authority
ES
Spain
Prior art keywords
monglicerido
pharmaceutical compositions
proteinase inhibitor
compositions
monoglycered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96921929T
Other languages
English (en)
Inventor
Carole Anne Bailey
Josephine Christine Ferdinando
Navnit Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/616,233 external-priority patent/US6008228A/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2182996T3 publication Critical patent/ES2182996T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES QUE AUMENTAN LA BIODISPONIBILIDAD DE INHIBIDORES DE PROTEINASA. LAS COMPOSICIONES INCLUYEN UN VEHICULO FARMACEUTICAMENTE ACEPTABLE QUE INCLUYE MONOGLICERIDOS DE ACIDOS GRASOS DE CADENA DE LONGITUD MEDIA.
ES96921929T 1995-06-06 1996-06-04 Composiciones farmaceuticas que comprenden un inhibidor de proteinasa y un monglicerido. Expired - Lifetime ES2182996T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46849395A 1995-06-06 1995-06-06
US08/616,233 US6008228A (en) 1995-06-06 1996-05-07 Pharmaceutical compositions containing proteinase inhibitors

Publications (1)

Publication Number Publication Date
ES2182996T3 true ES2182996T3 (es) 2003-03-16

Family

ID=27042422

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96921929T Expired - Lifetime ES2182996T3 (es) 1995-06-06 1996-06-04 Composiciones farmaceuticas que comprenden un inhibidor de proteinasa y un monglicerido.

Country Status (26)

Country Link
EP (1) EP0831826B1 (es)
JP (1) JP3238412B2 (es)
CN (1) CN1092960C (es)
AT (1) ATE226075T1 (es)
AU (1) AU709796B2 (es)
BG (1) BG63711B1 (es)
BR (1) BR9610842A (es)
CA (1) CA2224125C (es)
CY (1) CY2373B1 (es)
CZ (1) CZ292192B6 (es)
DE (1) DE69624354T2 (es)
DK (1) DK0831826T3 (es)
EA (1) EA001413B1 (es)
ES (1) ES2182996T3 (es)
HU (1) HU223899B1 (es)
IL (1) IL122353A0 (es)
IS (1) IS2661B (es)
MX (1) MX9709193A (es)
NO (1) NO324531B1 (es)
NZ (1) NZ311646A (es)
OA (1) OA10546A (es)
PL (1) PL184820B1 (es)
PT (1) PT831826E (es)
SK (1) SK282121B6 (es)
TR (1) TR199701541T1 (es)
WO (1) WO1996039142A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4524367B2 (ja) 1997-07-29 2010-08-18 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 自己乳化性処方形態の酸性親油性化合物用の医薬組成物
DK0999838T3 (da) * 1997-07-29 2002-07-08 Upjohn Co Selv-emulgerende formulering for lipofile forbindelser
EP1152749B1 (en) * 1999-02-08 2006-04-12 ALZA Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BR0202252A (pt) 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP2108705A1 (en) 2008-04-08 2009-10-14 Universität Duisburg-Essen Method for analysing the epigenetic status of the HtrA 1 gene in a biological sample
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
ATE226075T1 (de) 2002-11-15
HK1010136A1 (en) 1999-06-17
TR199701541T1 (xx) 1998-03-21
JPH10507202A (ja) 1998-07-14
EA199800023A1 (ru) 1998-08-27
CA2224125A1 (en) 1996-12-12
WO1996039142A1 (en) 1996-12-12
CN1092960C (zh) 2002-10-23
HUP9801905A2 (hu) 1999-05-28
NO975665D0 (no) 1997-12-05
AU709796B2 (en) 1999-09-09
BG102106A (en) 1998-08-31
PL323860A1 (en) 1998-04-27
JP3238412B2 (ja) 2001-12-17
CA2224125C (en) 2004-09-28
EP0831826A1 (en) 1998-04-01
BR9610842A (pt) 1999-07-13
NO975665L (no) 1998-02-05
SK162797A3 (en) 1998-05-06
AU6300496A (en) 1996-12-24
CZ380397A3 (cs) 1998-03-18
NO324531B1 (no) 2007-11-12
EP0831826B1 (en) 2002-10-16
IL122353A0 (en) 1998-04-05
OA10546A (en) 2002-05-29
CY2373B1 (en) 2004-06-04
DE69624354T2 (de) 2003-06-05
HU223899B1 (hu) 2005-03-29
BG63711B1 (bg) 2002-10-31
CZ292192B6 (cs) 2003-08-13
PL184820B1 (pl) 2002-12-31
NZ311646A (en) 2000-02-28
HUP9801905A3 (en) 2001-04-28
DK0831826T3 (da) 2003-02-03
CN1186434A (zh) 1998-07-01
IS4627A (is) 1997-12-04
DE69624354D1 (de) 2002-11-21
IS2661B (is) 2010-08-15
MX9709193A (es) 1998-03-31
EA001413B1 (ru) 2001-02-26
SK282121B6 (sk) 2001-11-06
PT831826E (pt) 2003-02-28

Similar Documents

Publication Publication Date Title
PT831826E (pt) Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo
PT722439E (pt) Inibidores da protease de hiv
NL300339I1 (nl) Sulfonamidederivaten als progeneesmiddelen van aspartylproteaseremmers
DE59610329D1 (de) Airblast-Zerstäuberdüse
FI951250A7 (fi) Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot
MA26492A1 (fr) Inhibiteurs de proteases nouveaux et compositions pharmaceutiques les contenant .
IT1289546B1 (it) Dispositivo di alimentazione e scarico di olio per compressore
DK0891362T3 (da) Pyrrolopyrrolon derivater som inhibitorer for neutrofil elastase
UY24248A1 (es) Composiciones farmacéuticas que contienen inhibidores de proteinasa
FI962488A7 (fi) HIV:n proteaasin inhibiittoreita
SE9601556D0 (sv) New pharmaceutical formulation of a thrombin inhibitor for parenteral use
NO964616D0 (no) Höytrykks-fluidkoplingsanordning
FI962073A0 (fi) HIV-proteaasin estäjän prodrug-muotoja
TR199501429A2 (tr) Matriks metaloproteaz inhibitörlerinin yerine gecen 4-biarilpentanoik asitleri ve türevleri
DE69404926D1 (de) Hochdruck-Entladungslampe
DE69526657D1 (de) Niederdruckentladungslampe
DE69606699D1 (de) Hochdruckentladungslampe
DE69608261D1 (de) Niederdruckentladungslampe
DE69633040D1 (de) Inhibitor der hornhaut-vaskularisation
ECSP961778A (es) Composiciones que incrementan la biodisponibilidad de inhibidores de proteinasa
EP0832651A4 (en) LIPID PEROXIDE INCREASE inhibitors
BR9612344A (pt) Inibidores de proteases
KR970019465U (ko) 콤팩트디스크플레어의 디스크 인출장치
EE04093B1 (et) HIV proteaasi inhibiitorit VX 478 ja vees lahustuva vitamiin E derivaati vitamiin E-TPGSi sisaldavad preparaadid
KR970025641U (ko) 브라운관의 스포트 불량제거용 소켓